We transform any smartphone into a measurement laboratory for precision medicine development
A digital endpoint can reduce sample size and/or augment probability of success (PoS) of R&D proof-of-concept (PoC) trials through two strategies:
Use a digital measurement with higher Signal-to-Noise Ratio (SNR) as a decision-enabling proof-of-concept (PoC) trial endpoint.
Does not have to be fully convergent with reference measurement, while enhancing the end of Phase II decision trees to optimise probability of success (PoS) in Phase III.
Use higher longitudinal frequency of digital measurements that correlate with the reference measurement
These digital markers can then help “explain” the variation, reduce the noise, and increase the SNR for the reference measurement.
Through our multi-year strategic collaboration with Biogen, we aim to expand the reach of our unique technology into Parkinson’s disease, a critical disease area where innovation is crucially needed.
The extension of our work into Parkinson’s disease may cross-fertilize with the progress of our scientific efforts in Multiple Sclerosis.
Indivi's focus on digital endpoint development spans across key neurodegenerative disorders, including Alzheimer’s disease, and related dementias.